1662TiP HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)

Q. Qin(Southwestern Medical Center), Tingwei Zhang(Chinese Academy of Sciences), Kevin D. Courtney(The University of Texas Southwestern Medical Center), Chen Chen Jiang(Hunter Medical Research Institute), Shaofeng Zhang(Southwestern Medical Center), Waddah Arafat(Southwestern Medical Center), E. Heath(The Barbara Ann Karmanos Cancer Institute), Jing Wang(Shanghai Jiao Tong University), Suzanne Cole(National Cancer Institute), Rafał Płoski(Medical University of Warsaw)
Annals of Oncology
September 1, 2024
Cited by 0


Related Papers